MICHAEL S. BROWN, M.D. - Corporate Board Profile

REGENERON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2016-04-26	MICHAEL S. BROWN, M.D., 75, has been a Director of the Company since June 1991. Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, and Foreign Member of the Royal Society (London). Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012. Dr. Brown's distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his significant industry experience gained through his service on the board of directors of the Company and of a leading pharmaceutical company, led to the board to conclude that Dr. Brown should serve as a director.
2017-04-25	Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. ... Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012. ... Compensation of Directors: Michael S. Brown, M.D. 2,109,085.
2018-04-23	MICHAEL S. BROWN, M.D. Director since: 1991 Age: 76 Independent Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, and Foreign Member of the Royal Society of London. Dr. Brown retired as a member of the board of directors of Pfizer Inc. in 2012. Board and Committee Membership: Board of Directors, Corporate Governance and Compliance Committee, Technology Committee (Chairman), Compensation Committee. Compensation of Directors table shows $1,232,211 option awards, $85,000 fees earned in cash, and $4,000 all other compensation totaling $1,321,211.
2019-04-26	Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. ... Board and Committee Membership — 2018 Attendance: Board of Directors 6/6, Corporate Governance and Compliance Committee 5/5, Technology Committee (Chairman) 3/3. ... Director Compensation Table: Michael S. Brown, M.D. Fees earned or paid in cash ($) 85,000, Option awards ($) 1,143,907, All other compensation ($) 5,000, Total ($) 1,233,907.
2021-04-23	Dr. Brown holds the Distinguished Chair in Biomedical Sciences, a position he has held since 1989, and is a Regental Professor of Molecular Genetics and Internal Medicine, and the Director of the Jonsson Center for Molecular Genetics, at The University of Texas Southwestern Medical Center at Dallas, positions he has held since 1985. Drs. Brown and Goldstein jointly received the Nobel Prize for Physiology or Medicine in 1985 and the U.S. National Medal of Science in 1988. Dr. Brown is a member of the National Academy of Sciences, the National Academy of Medicine, and Foreign Member of the Royal Society of London. Dr. Brown's distinguished scientific and academic background, including his receipt of the Nobel Prize for Physiology or Medicine in 1985, and his significant industry experience gained through his service on the board of directors of the Company and of a leading pharmaceutical company, led the board to conclude that Dr. Brown should serve as a director. Board and Committee Membership—2020 Attendance: Board of Directors: 11/11 Corporate Governance and Compliance Committee: 5/5 Technology Committee (Chairman): 3/3 Prior Voting Results—2019: For: 70.7% Against: 29.3% Regeneron Securities Beneficially Owned as of April 13, 2021: Common Stock: 15,349 Options: 28,625 RSUs: 750
2022-04-21	Michael S. Brown, M.D. Director since: 1991 Age: 80 Independent Board and Committee Membership–2021 Attendance Board of Directors: 9/9 Corporate Governance and Compliance Committee: 5/5 Technology Committee (Chair): 2/2 Director Compensation Table: Michael S. Brown, M.D. Total: 725,094
2024-04-25	Michael S. Brown, M.D. - Director since 1991, Age 83. Board and Committee Membership—2023 Attendance: Technology Committee. Compensation: $728,987.